Biodexa Pharmaceuticals annual shares outstanding
2017
2018
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Shares Outstanding History (BDRX)
Biodexa Pharmaceuticals reported 225.82B shares outstanding at the end of fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 225.82B | 219.13B | +3277.51% |
| 2024 | 2024-12-31 | 6.69B | 5.50B | +462.04% |
| 2023 | 2023-12-31 | 1.19B | 1.18B | +21859.53% |
| 2022 | 2022-12-31 | 5.4M | −6.73B | −99.92% |
| 2021 | 2021-12-31 | 6.74B | −306.8M | −4.35% |
| 2020 | 2020-12-31 | 7.05B | — | — |
| 2018 | 2018-12-31 | 61.2M | 100,000 | +0.16% |
| 2017 | 2017-12-31 | 61.1M | — | — |
Biodexa Pharmaceuticals quarterly shares outstanding
Q4.17
Q4.18
Q4.20
Q4.21
Q4.22
Q4.23
Q1.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 225.82B | 219.13B | +3277.51% |
| Q2 2025 | 2025-06-30 | 61.95B | — | — |
| Q4 2024 | 2024-12-31 | 6.69B | 5.50B | +462.04% |
| Q1 2024 | 2024-04-25 | 6.69B | — | — |
| Q4 2023 | 2023-12-31 | 1.19B | 1.18B | +21859.53% |
| Q4 2022 | 2022-12-31 | 5.4M | −6.73B | −99.92% |
| Q4 2021 | 2021-12-31 | 6.74B | −306.8M | −4.35% |
| Q4 2020 | 2020-12-31 | 7.05B | — | — |
| Q4 2018 | 2018-12-31 | 61.2M | 100,000 | +0.16% |
| Q4 2017 | 2017-12-31 | 61.1M | — | — |
Biodexa Pharmaceuticals shares outstanding trends
Over the last five fiscal years, Biodexa Pharmaceuticals's shares outstanding moved from 7.05B to 225.82B, a change of 218.77B. The latest reported quarter, Q4 2025, shows 225.82B.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...
